Treatment of Deep Venous Thrombosis With Low-Molecular-Weight Heparins: A Meta-analysis

Archives of Internal Medicine

Volumn 155, Issue 6, 1995, Pages 601-607

  Lensing, Anthonie W A ^a   Prins, Martin H ^a   Davidson, Bruce L ^b   Hirsh, Jack ^c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Hamilton ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CY 222; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM;

HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INCIDENCE; PHLEBOGRAPHY; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; THROMBOPHLEBITIS;

EID: 0028939906     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.1995.00430060059007     Document Type: Article

References (37)

1. Hirsh J. Heparin. N Engl J Med. 1991;324:1565-1574.
2. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the treatment of proximal-vein thrombosis. N Engl J Med. 1986;315:1109-1114.
3. Gallus A, Jackaman J, Tillet J, Mills W, Wycherley A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet. 1986;2:1293-1296.
4. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1990;322:1260-1266.
5. Brandies DPM, Heijboer H, Büller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1992;327:1485-1489.
6. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med. 1972;287:325-327.
7. Young E, Prins MH, Levine MN, Hirsh J. Heparin binding to plasma proteins: an important mechanism for heparin resistance. Thromb Haemost. 1992;67: 639-643.
8. Hirsh J. From unfractionated heparins to low molecular weight heparins. Acta Chir Scand Suppl. 1990;556:42-50.
9. Hirsh J, Levine MN. Low molecular weight heparin. Blood. 1992;79:1-17.
10. Nurmohamed MT, Rosendaal FR, Büller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet. 1992;340:152-156.
11. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Deciding on best therapy. In: Clinical Epidemiology: A Basic Science for Clinical Medicine. Boston, Mass: Little Brown & Co Inc; 1985:187-248.
12. Büller HR, Lensing AWA, Hirsh J, ten Cate JW. Deep venous thrombosis: new noninvasive tests. Thromb Haemost. 1991;66:133-139.
13. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
14. Collins R, Gray R, Godwin J, Peto R. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. Stat Med. 1987;6:245-250.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
16. Notarbartolo A, Salanitri G, Davi G, Averna M, Barbagallo C, Catalano I. Low molecular weight heparin in the short and long-term treatment of deep vein thrombosis in diabetic subjects. Med Prax. 1988:9:393-405.
17. Zanghi M, Morici V, Costanzo M, Astuto L, Salanitri G. Deep vein thrombosis of the legs: new therapy by means of low molecular weight heparins. J Intern Med Res. 1988;16:474-484.
18. Tedoldi A, Botticella F, Maloberti MR. Antithrombophilic effect of low molecular weight heparins in patients with deep vein thrombosis. Clin Trials Meta-analysis. 1993;28:215-225.
19. Handeland GF, Abildgaard U, Holm HA, Arnesen KE. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol. 1990;39:107-112.
20. Lockner D, Bratt G, Tornebohm E, Aberg W, Granqvist S. Intravenous and subcutaneous administration of Fragmin in deep venous thrombosis. Haemostasis. 1986;16(suppl):25-29.
21. Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Circulation. 1989;80: 935-940.
22. Harenberg J, Huck K, Bratsch H, et al. Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis. Haemostasis. 1990;20:205-219.
23. Momanmäki K, Hallen C, Kim H, Finnish Multicentre Group. Low molecular weight heparin (Fragmin) once daily versus continuous infusion of standard heparin in the treatment of DVT. Haemostasis. 1994;24(suppl 1):248. Abstract.
24. Fiessinger JN, Fernandez ML, Gatterer E, Ohlsson CG. Fragmin once daily versus continuous infusion heparin in the treatment of DVT: a European multicentre trial. Haemostasis. 1994;24(suppl 1):44. Abstract.
25. Bratt G, Tornebohm E, Granqvist S, Aberg W, Lockner D. A comparison between low molecular weight heparin Kabi 2165 and standard heparin in the intravenous treatment of deep vein thrombosis. Thromb Haemost. 1985:85: 813.
26. Holm HA, Ly B, Handeland GF, et al. Subcutaneous heparin treatment of deep vein thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis. 1986;16(suppl):30-37.
27. Faivre R, Neuhart E, Kieffer Y, Toulemonde F, Bassand JP, Maurat JP. Subcutaneous administration of a low molecular weight heparin (CY 222) compared with subcutaneous administration of standard heparin in patients with acute deep vein thrombosis. Thromb Haemost. 1987;58(suppl):120. Abstract 430.
28. Bratt G, Aberg W, Johansson M, Tornebohm E, Granqvist S, Lockner D. Two daily subcutaneous injections of Fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis. Thromb Haemost. 1990;64:506-510.
29. Duroux P. A Collaborative European Multicentre Study: a randomized trial of subcutaneous low molecular weight heparin (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost. 1991;65:251-256.
30. Prandoni P, Lensing AWA, Büller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deepvein thrombosis. Lancet. 1992;339:441-445.
31. Lopaciuk S, Meissner AJ, Filipecki S, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemost. 1992:68:14-18.
32. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximalvein thrombosis. N Engl J Med. 1992;326:975-982.
33. Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the initial treatment proximal vein thrombosis. Arch Intern Med. 1993;153: 1541-1546.
34. Lindmarker P, Holmström M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thromb Haemost. 1994;72:186-190.
35. Anderson DR, O'Brien BJ, Levine MN, Roberts R, Wells PS, Hirsh J. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med. 1993;119:1105-1112.
36. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ. 1994;309: 299-304.
37. Oxman AD. Checklist for review articles. BMJ. 1994;309:648-651.